Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

More documents

Recommendations

Info

1-2 Cardiovascular Pharmacotherapeutics Tracy TS: Metabolism and excretion of drugs. In Craig CR, Stizel RE (eds): Modern Pharmacology 6th ed. New York: Lippincott Williams & Wilkins 2004; 34–47. Tracy TS: Pharmacokinetics. In Craig CR, Stizel RE (eds): Modern Pharmacology 6th ed. New York: Lippincott Williams & Wilkins 2004; 48–55.
References for Chapter 5 Alpha- and Beta-Adrenergic Blocking Drugs William H. Frishman, MD 1. Ahlquist RP: Study of the adrenotropic receptors. Am J Physiol 153:486, 1948. 2. Lands AM, Luduena FP, Buzzo HJ: Differentiation of receptor systems responsive to isoproterenol. Life Sci 6:2241, 1967. 3. Emorine LJ, Marullo S, Briend-Sutren M-M, et al: Molecular characterization of the human b 3 -adrenergic receptor. Science 245:1118, 1989. 4. Berthelsen S, Pettinger WA: A functional basis for classification of alpha-adrenergic receptors. Life Sci 21:596, 1977. 5. Berecek KH, Carey RM: Adrenergic and dopaminergic receptors and actions. In Izzo JL Jr, Sica DA, Black HR: Hypertension Primer 4th ed. Dallas: American Heart Assn 2008: 39. 6. Sutherland EW, Robinson GA, Butcher RW: Some aspects of the biological role of adenosine 3ʹ5ʹ-monophosphate (cyclic AMP). Circulation 37:279– 306, 1968. 7. Insel PA: Adrenergic receptors: evolving concepts and clinical implications. N Engl J Med 334:580, 1996. 8. Lefkowitz RJ, Caron MG: Adrenergic receptors: models for the study of receptors coupled to guanine nucleotide regulatory proteins. J Biol Chem 263:4993–4996, 1988. 9. Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ: Regulation of adenyl cyclase-coupled beta-adrenergic receptors. Annu Rev Cell Biol 4:405–428, 1988. 10. Lefkowitz RJ: Seven transmembrane receptors: something old, something new. Acta Physiol 190: 9-19, 2007. 11. Watanabe AM: Recent advances in knowledge about beta-adrenergic receptors: application to clinical cardiology. J Am Coll Cardiol 1:82–89, 1983. 12. Frishman WH, Charlap S: a-Adrenergic blockers. Med Clin North Am 72:427, 1988. 13. Pool JL: a-Adrenoceptor antagonists. In Izzo JL Jr, Sica DA, Black HR: Hypertension Primer 4th ed. Dallas: American Heart Assn 2008: 450. 14. Katz AM, Hager WD, Mesineo FC, et al: Cellular actions and pharmacology of the calcium channel blocking drugs. Am J Med 77:2, 1984. 15. Ribner HS, Bresnahan D, Hsieh AM: Acute hemodynamic responses to vasodilation therapy in congestive heart failure. Prog Cardiovasc Dis 25:1, 1982. 16. Neaton JD, Grimm RH, Prineas RI, et al for the Treatment of Mild Hypertension Study Research Group: treatment of mild hypertension study: final results. JAMA 270:713, 1993. 17. Materson BJ, Reda DJ, Cushman WC, et al: Singledrug therapy for hypertension in men. A comparison of six antihypertensives with placebo. N Engl J Med 328:914, 1994. 18. Davis BR, Cutler JA, Gordon DJ, et al, for the ALL- HAT Research Group: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9:342, 1996. 19. The ALLHAT Off\hskip.1pticers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283:1967, 2000. 20. Frishman WH: Update in cardiology. Ann Intern Med 135:439, 2001. 21. Davis BR, Cutler JA, Furberg CD, et al: Relationship of antihypertensive treatment regimens and change Cardiovascular Pharmacotherapeutics, 3rd ed, Abridged and Updated. © 2012 William H. Frishman and Domenic A. Sica, eds. Cardiotext Publishing, ISBN: 978-1-935395-52-2. 5-1
Page 1: Supplemental Reading for Chapter 1
Page 5 and 6: cardial infarction. N Engl J Med 31
Page 7 and 8: 113. Meister SG, Engel TR, Feitosa
Page 9 and 10: gy of propranolol in man. Circulati
Page 11 and 12: trial. J Am Coll Cardiol 34:325, 19
Page 13 and 14: ceed? JAMA 285:2604, 2001. 269. Sou
Page 15 and 16: failure receiving inotropic therapy
Page 17 and 18: cotherapy of glaucoma and ocular hy
Page 19 and 20: References for Chapter 6 Central an
Page 21: 48. Fahlke C, Berggren U, Balldin J
Page 24 and 25: 7-2 Cardiovascular Pharmacotherapeu
Page 34 and 35: 8-10 Cardiovascular Pharmacotherape
Page 53 and 54:
References for Chapter 10 The Renin
Page 55 and 56:
tatine- and difluorostatone-contain
Page 57:
102. Solomon SD, Appelbaum E, Manni
Page 60 and 61:
11-2 Cardiovascular Pharmacotherape
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
11-10 Cardiovascular Pharmacotherap
Page 70 and 71:
11-12 Cardiovascular Pharmacotherap
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 95 and 96:
References for Chapter 16 Nonspecif
Page 97 and 98:
References for Chapter 17 Antiarrhy
Page 99 and 100:
alters the disposition of procainam
Page 101 and 102:
ment of early ventricular tachyarrh
Page 103 and 104:
115(1Pt 1):92, 1988. 161. Prystowsk
Page 105 and 106:
219. Gonzalez R, Scheinman MM, Herr
Page 107 and 108:
the atrioventricular node of verapa
Page 109 and 110:
References for Chapter 18 Antiplate
Page 111 and 112:
44. Berger JS, Roncaglioni MC, Avan
Page 113 and 114:
tance. Mechanisms and clinical impl
Page 115 and 116:
J 157: e1, 2009. 143. Bonello L, Ca
Page 117 and 118:
out a glycoprotein IIb/IIIa inhibit
Page 119 and 120:
from the PROTECT-TIMI-30 trial. J A
Page 121 and 122:
AHA guidelines for the management o
Page 123 and 124:
nary angioplasty. The EMPAR Study.
Page 125 and 126:
domized double-blind comparison of
Page 127 and 128:
quirements in an adult Turkish popu
Page 129 and 130:
1261, 2007. 455. Gresele P, Deckymy
Page 131 and 132:
498. Jeong YH, Lee SW, Choi BR, et
Page 133:
530. Konishi N, Hiroe K, Sinozawa E
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 143 and 144:
References for Chapter 20 Lipid-Low
Page 145 and 146:
lipid lowering with atorvastatin in
Page 147 and 148:
emia in diabetes. Cardiol in Rev 14
Page 149 and 150:
140. Olivari MT, Homans DC, Wilson
Page 151 and 152:
poprotein cholesterol and coronary
Page 153 and 154:
ary lipid secretion in patients wit
Page 155 and 156:
and the risk of cancer. Arch Intern
Page 157 and 158:
center comparative trial of lovasta
Page 159 and 160:
of rosuvastatin therapy on coronary
Page 161 and 162:
nicotinic acid on serum cholesterol
Page 163 and 164:
PC: Cardiovascular effects of marin
Page 165 and 166:
protein cholesterol lowering in pat
Page 167 and 168:
tice. N Engl J Med 349:1587, 2003.
Page 169 and 170:
compound NO-1886 elevates plasma hi
Page 171:
cardiovascular system. Cardiol in R
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 205 and 206:
References for Chapter 26 Selective
Page 207:
lot trial in the prevention of cont
Page 210 and 211:
Page 213 and 214:
References for Chapter 28 Vasopress
Page 215 and 216:
Eur J Pharmacol 1999; 26: 89-94. 50
Page 217 and 218:
Am J Med 119 Suppl 1: S47, 2006. 10
Page 219 and 220:
References for Chapter 29 Drug-Elut
Page 221 and 222:
able stents. Expert Opin Drug Deliv
Page 223:
ing stents over bare metal stents i
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238:
show all

Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?